CYTOKINETICS (CYTK) EVP Malik exercises options, sells 3,500 shares, keeps large stake

Rhea-AI Filing Summary

CYTOKINETICS INC EVP of Research & Development Fady Ibraham Malik executed an option exercise and sale in company stock. On June 23, 2026, he exercised options to acquire 3,500 shares of common stock at $7.80 per share, then sold 3,500 shares in an open-market transaction at an average price of $79.51 per share. Following these transactions, he directly held 153,902 shares of common stock and 40,886 non-qualified stock options.

Insights

Insider trading analyst

EVP executes 3,500-share option exercise-and-sale, retains sizable position.

EVP of Research & Development Fady Ibraham Malik exercised non-qualified stock options for 3,500 shares of CYTOKINETICS INC common stock at a strike price of $7.80 per share, then sold the same number of shares at $79.51 per share in an open-market transaction.

This pattern reflects an exercise-and-sell sequence, turning a derivative award into cash while maintaining ongoing exposure through 153,902 common shares and 40,886 remaining options as of the reported date. The filing shows net-sell activity of 3,500 shares but with substantial holdings left.

Given the modest size of the sale relative to reported holdings and the absence of additional context such as a trading plan in the excerpt, this appears consistent with routine liquidity or compensation-related portfolio management rather than a transformative change in insider positioning.

Insider Trade Summary 10b5-1

Net Seller: 3,500 shares ($278,285)

Net Sell 3 txns

Insider Malik Fady Ibraham

Role EVP Research & Development

Sold 3,500 shs ($278K)

Type	Security	Shares	Price	Value
Exercise	Non-Qualified Stock Option (Right to Buy)	3,500	$0.00	--
Exercise	Common Stock	3,500	$7.80	$27K
Sale	Common Stock	3,500	$79.51	$278K

Holdings After Transaction: Non-Qualified Stock Option (Right to Buy) — 40,886 shares (Direct, null); Common Stock — 157,402 shares (Direct, null)

Footnotes (1)

Key Figures

Shares sold: 3,500 shares Sale price: $79.51 per share Options exercised: 3,500 shares +4 more

7 metrics

Shares sold 3,500 shares Open-market sale of common stock on June 23, 2026

Sale price $79.51 per share Average price for 3,500-share sale

Options exercised 3,500 shares Non-qualified stock option exercise into common stock

Option exercise price $7.80 per share Conversion or exercise price of non-qualified stock option

Shares held after transaction 153,902 shares Direct common stock holdings following transactions

Options remaining 40,886 options Non-qualified stock options outstanding after exercise

Transaction date June 23, 2026 Date of option exercise and share sale

Key Terms

open-market sale, Non-Qualified Stock Option (Right to Buy), derivative exercise/conversion, Common Stock, +1 more

5 terms

open-market sale financial

"transaction_action: "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Non-Qualified Stock Option (Right to Buy) financial

"security_title: "Non-Qualified Stock Option (Right to Buy)""

derivative exercise/conversion financial

"transaction_action: "derivative exercise/conversion""

Common Stock financial

"security_title: "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

net-sell financial

"transactionSummary: "netBuySellDirection": "net-sell""

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/23/2026 - 05:42 PM Accepted by SEC EDGAR 06/23/2026 - 05:41 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Malik Fady Ibraham

(Last) (First) (Middle)

350 OYSTER POINT BLVD

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CYTOKINETICS INC [ CYTK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP Research & Development

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/23/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/23/2026		M		3,500	A	$7.8	157,402	D
Common Stock	06/23/2026		S		3,500	D	$79.51	153,902	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Non-Qualified Stock Option (Right to Buy)	$7.8	06/23/2026		M			3,500	03/27/2018	02/27/2028	Common Stock	3,500	$0	40,886	D

Explanation of Responses:

	/s/ John O. Faurescu, attorney-in-fact for Dr. Malik	06/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did CYTOKINETICS (CYTK) executive Fady Malik do in this Form 4 filing?

Fady Malik exercised options for 3,500 CYTOKINETICS shares at $7.80 and sold 3,500 shares at $79.51. The filing shows a classic exercise-and-sale, converting an equity award into cash while retaining a substantial remaining equity stake.

How many CYTOKINETICS (CYTK) shares did Fady Malik sell, and at what price?

He sold 3,500 CYTOKINETICS common shares in an open-market transaction at an average price of $79.51 per share. This sale followed an option exercise for the same number of shares on the same reported date.

What options did Fady Malik exercise in the latest CYTOKINETICS (CYTK) Form 4?

He exercised a Non-Qualified Stock Option for 3,500 underlying CYTOKINETICS common shares at a conversion or exercise price of $7.80 per share. The option was originally granted with an expiration date in 2028, according to the filing data.

How many CYTOKINETICS (CYTK) shares does Fady Malik hold after these transactions?

After the reported transactions, Fady Malik directly holds 153,902 CYTOKINETICS common shares. He also retains 40,886 non-qualified stock options, providing additional potential equity exposure beyond his current share ownership level.

What is the net effect of Fady Malik’s CYTOKINETICS (CYTK) trades on his share count?

The filing shows net-sell activity of 3,500 shares. He exercised options to acquire 3,500 shares, then sold 3,500 shares, ending with 153,902 common shares and 40,886 remaining options according to the transaction and derivative summaries.

Was Fady Malik’s CYTOKINETICS (CYTK) transaction an open-market sale?

Yes. The Form 4 classifies the transaction with code S as an open-market or private sale. It specifies a 3,500-share sale of common stock at an average price of $79.51 per share, categorized as an open-market sale.